Elimite
(Permethrin)ApprovedSmall molecule
Elimite is one of 53 small molecule programs targeting Malaria. It is currently in Approved.
2
Indications
10
Total Trials
0
Active Trials
52
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
79 competitors in Malaria
#DrugCompanyPhaseTrials
1Dihydroartemisinin-Piperaquine
GSKPhase 3
Rabies Vaccine
NovartisPhase 3
Elimite
DDT MedTech, LLC
Approved
Krintafel
GGlaxo Dba Glaxosmithkline
Phase 3
Artemether-Lumefantrine (AL)
NovartisPhase 3
Artesunate-Amodiaquine
SanofiPhase 3
R21/matrix-M
UUniversity of Oxford
Phase 3
Pyramax
SShin Poong Pharmaceutical Co. Ltd.
Phase 3
Biltricide
BayerPreclinical
Stelara
Johnson & JohnsonPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Treatment3 trials
A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies
Completed·—·Phase 3·NCT02572986·250 enrolled
Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies
Completed·—·Phase 1·NCT05862701·60 enrolled
Comparative Study Between Topical Permethrin 5% and Oral Ivermectin for the Treatment of Scabies
Completed·—·Phase 1·NCT05362513·100 enrolled
Children2 trials
Scabies2 trials
Sulfur vs. Different Regimes of Permethrin for Scabies
Completed·—·Phase 3·NCT06396507·250 enrolled
1 more indication
Malaria1 trial
Malaria Elimination Pilot Study in Military Forces in Cambodia
Unknown status·—·Phase 4·NCT02653898·1,050 enrolled
Regulatory
FDA Approval Timeline[4]
Mar 31, 1986
NIX
NDA NDA019435
Aug 25, 1989
ELIMITE
NDA NDA019855
May 2, 1990
NIX
NDA NDA019918
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Permethrin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- DDT MedTech, LLC